Objectives: To test the activity of tigecycline combined with 16 antimicrobials in vitro against 22 Gram-positive and 55 Gram-negative clinical isolates.
Introduction
Tigecycline is the first glycylcycline antibiotic available for clinical use. 1 Tigecycline is highly active in vitro against most common Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate S. aureus (GISA), penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci and extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae. 1 -3 The activity of tigecycline is not affected by common tetracycline resistance mechanisms, including tetracycline-specific efflux pumps and ribosomal protection. Nevertheless, some isolates tend to have decreased susceptibility to tigecycline (Proteus mirabilis, indole-positive Proteus spp., Morganella morganii, Providencia spp. and a few strains of Serratia marcescens and K. pneumoniae) or demonstrate resistance (Pseudomonas aeruginosa). 2, 3 These strains have constitutively overexpressed multidrug efflux pump systems for which tigecycline is a substrate, such as AcrAB in P. mirabilis, M. morganii and K. pneumoniae 4 -6 and MexXY in P. aeruginosa. 7 The present study investigated the effect of combining tigecycline with other antibacterials against representative clinical isolates of Gram-positive and Gram-negative organisms.
Materials and methods

Microorganisms
A total of 77 bacterial isolates (22 Gram-positive and 55 Gramnegative) were tested (Table 1) . These isolates were recovered from human infections (one isolate per patient). Gram-positive isolates included six Enterococcus faecalis [five vancomycinsusceptible and one vancomycin-resistant (VanA type)], five Enterococcus faecium [four vancomycin-susceptible and one vancomycin-resistant (VanA type)], six S. aureus (two methicillin-susceptible S. aureus, three MRSA and one GISA) and five S. pneumoniae (three penicillin-susceptible and two penicillinresistant). Gram-negative isolates were chosen at random to represent a spectrum of bacteria and resistance phenotypes encountered in clinical practice, e.g. b-lactam-resistant, quinoloneresistant and/or trimethoprim/sulfamethoxazole-resistant strains, and included five isolates of each of the following species: Acinetobacter spp., Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, E. coli, K. pneumoniae, M. morganii, Proteus spp., P. aeruginosa, S. marcescens and Stenotrophomonas maltophilia.
Antimicrobial agents
The antibiotics tested in combination with tigecycline are shown in Table 1 . Tigecycline was provided by Wyeth Research (Pearl River, NY, USA). All the other drugs were commercially available products.
MIC determination
MICs were determined using the broth microdilution method in Mueller -Hinton broth (MHB). S. aureus ATCC 29213, E. faecalis ATCC 29212, E. coli ATCC 25922, K. pneumoniae ATCC 27736 and P. aeruginosa ATCC 27853 were used as quality control strains. Interpretative criteria for tigecycline MICs were defined on the basis of the United States Food and Drug Administration susceptibility breakpoints of 0.25 mg/L for streptococci and enterococci and 0.5 mg/L for S. aureus, and 2 mg/L for susceptibility, 4 mg/L for intermediate and !8 mg/ L for resistance when testing Gram-negative organisms. 1, 3 Chequerboard studies Antibiotic interactions were assessed by the chequerboard method in 96-well microtitre plates. The wells were inoculated with 10 5 cfu/mL, and the plates were incubated for 24 h at 358C. Fractional inhibitory concentrations (FICs) were calculated as the MIC of drug A or B in combination/the MIC of drug A or B alone, and the FIC index (FICI) was obtained by adding the FIC values. FICIs of 0.5 were interpreted as synergistic, those of .0.5 but 4 were considered as indifferent, and those of .4 were interpreted as antagonistic. 8, 9 Time -kill assays In selected cases, synergism and antagonism were also tested in time -kill experiments. Flasks containing MHB were inoculated with 10 6 cfu/mL of the test organism. For synergism, antibiotics were added to the flasks at concentrations equivalent to 0.25Â the MIC for the specific isolate. For testing the agreement with the only case of antagonism observed by the chequerboard results (tigecycline in combination with imipenem, each drug was tested alone at the following concentrations): tigecycline 0.25Â and 2Â the MIC, imipenem 0.032Â and 2Â the MIC; and in combination at the following concentrations: tigecycline 0.25Â the MIC plus imipenem 2Â the MIC, and tigecycline 2Â the MIC plus imipenem 0.032Â the MIC, i.e. the highest drug combinations showing turbidity in microtitre plates. Synergism, indifference and antagonism were defined as described previously. 8 Each time -kill experiment was repeated two times independently.
Results
Susceptibility results
Tigecycline was active (MIC 0.01 -0.5 mg/L) against all of the 22 Gram-positive isolates tested regardless of their resistance pattern to other drugs. For the 55 Gram-negative test organisms, tigecycline was active (MIC 2 mg/L) against 46 (84%), borderline against 4 (7%; 3 Proteus spp. and 1 M. morganii), and ineffective (MIC ! 8 mg/L) against 5 (9%; all being P. aeruginosa) isolates.
FICIs-Gram-positive isolates
Over the 286 individual antibiotic and bacteria combinations with the Gram-positive isolates ( Table 1) , synergism (FICI 0.5) occurred in 21 of 286 (7%) cases and indifference (FICI .0.5 but 4) in 265 of 286 (93%) cases, irrespective of the drug resistance pattern to other drugs. No antagonism (FICI .4) was detected. High rates of synergism occurred against Enterococcus spp. (synergism in 7 of 11 isolates) when tigecycline was combined with rifampicin. The combination of tigecycline with amoxicillin/clavulanate was also synergistic against two (both MRSA) of the six S. aureus isolates.
FICIs-Gram-negative isolates
Over the 605 individual antibiotic and bacteria combinations with the Gram-negative isolates (Table 1) , synergism occurred in 76 of 605 (13%) cases and indifference in 528 of 605 (87%) cases. Synergism was observed mainly with trimethoprim/ sulfamethoxazole against S. marcescens (five of five isolates), Proteus spp. (two of five) and S. maltophilia (two of five); with cefepime and imipenem against E. cloacae (three of five); with ceftazidime against M. morganii (three of five); with ceftriaxone against K. pneumoniae (three of five); and with aztreonam against S. maltophilia (three of five isolates). Other synergisms occurred in various isolates with various antibiotic combinations, including with amikacin against a total of 12 of the 55 organisms. Antagonism occurred only in one case (0.2% of the tests) with imipenem against an S. marcescens isolate.
Time-kill assays
In selected cases (three Gram-positive isolates and nine Gramnegative isolates), synergism or antagonism was further tested in time -kill experiments [see Figures S1 and S2, available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. For Gram-positive bacteria, time -kill experiments confirmed that tigecycline plus rifampicin against enterococci was more active than either drug alone. In addition, they revealed a bactericidal synergism between tigecycline and piperacillin/tazobactam against one penicillin-resistant pneumococcal isolate.
Time-kill experiments with Gram-negative isolates confirmed the bacteriostatic synergism between tigecycline and imipenem against E. cloacae 1085, tigecycline and ceftazidime against M. morganii 48, tigecycline and trimethoprim/sulfamethoxazole against P. mirabilis 119 and S. marcescens 220, tigecycline and amikacin against S. maltophilia 58 and P. mirabilis 35, and tigecycline and aztreonam against S. maltophilia 59. In addition, bactericidal synergism was observed between tigecycline and amikacin against Proteus vulgaris 60.
We also tested the only case of antagonism revealed by the chequerboard method against one isolate of S. marcescens. When 0.25Â MIC of tigecycline was mixed with increasing concentrations of imipenem, the MIC of imipenem reproducibly increased by 4Â. However, this antagonism was limited to this sub-MIC concentration and did not occur at greater concentrations of tigecycline. Likewise, when 0.032Â MIC of imipenem was added to increasing concentrations of tigecycline, the MIC of tigecycline consistently increased by 4Â. When we tested tigecycline in combination with imipenem by time -kill assays at the highest drug combinations showing turbidity in microplates, the antagonism was confirmed when tigecycline at 0.25Â the MIC was combined with imipenem at 2Â the MIC. However, antagonism was not detected when tigecycline at 2Â the MIC was combined with imipenem at 0.032Â the MIC.
The results of time -kill assays agreed reasonably well with the chequerboard method: for the 34 combinations examined with both methods, synergy results by chequerboard were confirmed by time -kill studies in 10/20 (50%) occasions, indifference in 11/13 (85%) and antagonism in 1/1 (100%).
Discussion
The present results indicate that the interaction of tigecycline with other drugs against Gram-positive and Gram-negative bacteria was essentially indifferent. Thus, tigecycline could be used safely with other antibacterial compounds, for instance, in empirical antibiotherapy requiring a very broad-spectrum antibiotic coverage or in intra-abdominal polymicrobial infection involving a possible tigecycline-resistant Pseudomonas. An antagonism was observed in only one single case (0.1% of cases), with tigecycline in combination with imipenem. This antagonism was limited to a very sub-MIC concentration of tigecycline (0.25Â the MIC). A speculative explanation for this observation is that sub-MIC concentrations of either of the drugs could induce drug efflux of the partner compound. As the phenomenon occurred in a restricted window of sub-MIC concentrations, its potential clinical relevance is unclear.
The fact that drug interactions between tigecycline and other compounds were essentially indifferent supports previous results using the chequerboard method. 10 However, the present experiments also revealed a number of interesting synergisms. These synergisms were of either of two types, i.e. (i) bacteriostatic, as observable by chequerboard and time-kill assays, and/or (ii) bactericidal, as revealed only by time-kill assays. Two of the synergisms revealed by the chequerboard method tended to be both drug-class and organism dependent, including tigecycline and rifampicin against Enterococcus spp. and tigecycline and trimethoprim/sulfamethoxazole against E. cloacae, Proteus spp. and S. maltophilia. Both synergisms could be of clinical relevance, as the organisms they target belong to potentially problematic multiresistant species. The generalization of these synergisms to additional isolates of these species and their possible relevance in infection models might be worth testing. Other synergisms were non-specifically spread over several drugs and organisms and might be more difficult to interpret. Eventually, time-kill assays disclosed a clear bactericidal synergism between tigecycline and b-lactams against one tested S. pneumoniae and tigecycline and amikacin against one tested P. vulgaris. Although these preliminary observations need to be investigated further, they might open new perspectives for the utilization of tigecycline with other antibacterials in specific types of infections.
